{
    "clinical_study": {
        "@rank": "10189", 
        "brief_summary": {
            "textblock": "This study is a 48-week study to evaluate the efficacy and safety of an investigational\n      regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on\n      their first highly active antiretroviral therapy regimen."
        }, 
        "brief_title": "Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure", 
        "completion_date": {
            "#text": "August 2004", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Currently on an initial HAART (highly active antiretroviral therapy) regimen of\n             3TC/ZDV or 3TC/d4T and a PI (protease inhibitor) -boosted or unboosted- or NNRTI\n             (non-nucleoside reverse transcriptase inhibitor).\n\n          -  Plasma HIV - 1 RNA was <400 copies/ml on at least 2 documented occasions prior to\n             viral rebound.\n\n          -  Have a plasma HIV - 1 RNA value >400 copies/ml and <10,000 copies/ml on 2 documented\n             successive occasions (including screen) separated by at least 2 weeks.\n\n          -  A CD4+ lymphocyte count less than or equal to 100.\n\n        Exclusion Criteria:\n\n          -  Have not taken Abacavir (ZIAGEN or TRIZIVIR) or tenofovir (VIREAD) previously.\n\n          -  Have not had an AIDS defining illness within 30 days of screen.\n\n          -  Pregnant or breast-feeding.\n\n          -  Specified viral genotypes upon screening.\n\n          -  And other inclusion or exclusion criteria to be evaluated by the physician."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "May 31, 2002", 
        "id_info": {
            "nct_id": "NCT00038506", 
            "org_study_id": "ESS 30005"
        }, 
        "intervention": [
            {
                "intervention_name": "abacavir/lamivudine/zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "tenofovir", 
                "intervention_type": "Drug", 
                "other_name": [
                    "abacavir/lamivudine/zidovudine", 
                    "tenofovir"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Lamivudine", 
                "Tenofovir", 
                "Tenofovir disoproxil", 
                "Abacavir", 
                "Lamivudine, zidovudine drug combination"
            ]
        }, 
        "keyword": "HIV-1 TRIZIVIR Tenofovir", 
        "lastchanged_date": "October 1, 2010", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90027"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Rafael", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94903"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Lauderdale", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33145"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32206"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Worth", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33463"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33139"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33161"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32804"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tallahassee", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32303"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30309"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30033"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60657"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maywood", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60153"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47904"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berkeley", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48072"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10461"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10014"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valhalla", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10595"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tulsa", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "74114"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76015"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75216"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75208"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77004"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Green Bay", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "54301"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensification Protocol)", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "HIV viral load response at 48 weeks as measured by proportion of subjects with undetectable viral load.", 
            "time_frame": "48 weeks"
        }, 
        "removed_countries": {
            "country": "South Africa"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038506"
        }, 
        "responsible_party": {
            "name_title": "Study Director", 
            "organization": "GSK"
        }, 
        "secondary_outcome": {
            "measure": "Safety Viral load response at 24 weeks Change in T-cell count Resistance Health outcomes", 
            "time_frame": "24 weeks"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2010"
    }, 
    "geocoordinates": {
        "GSK Investigational Site": "44.519 -88.02"
    }
}